Perrimond-Dauchy S - Search Results

Save citations to file

Email citations

Your saved search

Your RSS Feed

Page 1

Absence of QTc prolongation in a thorough QT study with imeglimin, a first in class oral agent for type 2 diabetes mellitus.

Dubourg J, Perrimond-Dauchy S, Felices M, Bolze S, Voiriot P, Fouqueray P. Dubourg J, et al. Among authors: perrimond dauchy s. Eur J Clin Pharmacol. 2020 Oct;76(10):1393-1400. doi: 10.1007/s00228-020-02929-6. Epub 2020 Jun 18. Eur J Clin Pharmacol. 2020. PMID: 32556539 Clinical Trial.

Imeglimin Does Not Induce Clinically Relevant Pharmacokinetic Interactions When Combined with Either Metformin or Sitagliptin in Healthy Subjects.

Fouqueray P, Perrimond-Dauchy S, Bolze S. Fouqueray P, et al. Among authors: perrimond dauchy s. Clin Pharmacokinet. 2020 Oct;59(10):1261-1271. doi: 10.1007/s40262-020-00886-y. Clin Pharmacokinet. 2020. PMID: 32270440 Clinical Trial.

Lack of Drug-Drug Interaction Between Cimetidine, a Renal Transporter Inhibitor, and Imeglimin, a Novel Oral Antidiabetic Drug, in Healthy Volunteers.

Chevalier C, Perrimond-Dauchy S, Dubourg J, Fouqueray P, Bolze S. Chevalier C, et al. Among authors: perrimond dauchy s. Eur J Drug Metab Pharmacokinet. 2020 Dec;45(6):725-733. doi: 10.1007/s13318-020-00642-4. Eur J Drug Metab Pharmacokinet. 2020. PMID: 32860624 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3 results

Search Page

Filters